Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study
DOACs had improved safety and effectiveness from bleeding and stroke/SE, respectively, versus VKAs among patients with NVAF at high risk for GIB. Apixaban was associated with lower MB and GIB risk versus other DOACs. For stroke/SE, apixaban was associated with reduced risk versus rivaroxaban and similar risk versus dabigatran.
Authors
- Nadia Quignot (ORCID: https://orcid.org/0000-0001-8718-1307)
- Robert Benamouzig (ORCID: https://orcid.org/0000-0003-1952-6830)
- Artak Khachatryan (ORCID: https://orcid.org/0000-0003-3888-2347)
- Gregory Y.H. Lip (ORCID: https://orcid.org/0000-0002-7566-1626)
- Gaëlle Gusto
- Giancarlo Pesce (ORCID: https://orcid.org/0000-0003-4925-6325)
- Ruth Mokgokong (ORCID: https://orcid.org/0000-0002-6278-4969)
- Feng Dai (ORCID: https://orcid.org/0000-0002-9963-6863)
- Anne‐Céline Martin (ORCID: https://orcid.org/0000-0002-6148-3523)
- Fouad Sedjelmaci
- José Chaves (ORCID: https://orcid.org/0000-0003-3820-3009)
Institutions
- University of Liverpool (GB)
- Inserm (FR)
- Pfizer (United States) (US)
- Saint Louis University (ES)
- Pfizer (United Kingdom) (GB)
- Université Paris Cité (FR)
- Liverpool Heart and Chest Hospital (GB)
- Hôpital Européen Georges-Pompidou (FR)
- Pfizer (France) (FR)
- Hôpital Avicenne (FR)
- Pfizer (Spain) (ES)
- Liverpool John Moores University (GB)
- Aalborg University (DK)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1371/journal.pone.0310322
- Citations
- 8
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- Bristol-Myers Squibb
- Pfizer
- National Institute for Health and Care Research
- European Commission
- Daiichi-Sankyo
- Conservatoire National des Arts et Métiers